The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

Penn sued BioNTech in August alleging the university was owed more in royalty payments for the use of the university's patented technology in a Covid-19 vaccine. BioNTech has agreed to pay the ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German ...

Penn has agreed to dismiss with prejudice the litigation Penn filed against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals, in the U.S. District Court for the Eastern District ...

Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...

Moreover, BioNTech's partner Pfizer (PFE) for its COVID-19 vaccine has agreed to reimburse the company for up to $170 million of the claimed royalties payable to Penn for 2020-2023 sales in ...

BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The ...

BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The ...

BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH ...